Few other investment vehicles have arguably done more to enrich investors than the U.S. stock market. For example, A $5,000 investment in the S 500 index executed 10 years ago in 2013 would be valued at $16,000 today with dividends reinvested. 

Pharmaceutical giant (NASDAQ: AMGN) is a component within the S 500 index. Having turned a $5,000 investment made in 2013 into $14,000 with dividends reinvested, its returns have moderately lagged the index. But here are three reasons why dividend growth investors may not regret adding Amgen to their portfolios. 

Since its founding in 1980, Amgen has devoted itself to fostering a culture of innovation. The company has routinely spent between 16% and 19% of its total revenue on research and development for years now. Major product launches such as the cholesterol-lowering drug Repatha, multiple myeloma treatment Kyprolis, and osteoporosis medicine Prolia have generated solid growth for the company.

Continue reading

Source Fool.com